CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23 | -17.9% | 504 | +2.6% | 0.01% | -28.6% |
Q2 2023 | $28 | +12.0% | 491 | -12.0% | 0.01% | +16.7% |
Q1 2023 | $25 | +19.0% | 558 | +5.7% | 0.01% | 0.0% |
Q4 2022 | $21 | -99.9% | 528 | +25.4% | 0.01% | -25.0% |
Q3 2022 | $28,000 | -6.7% | 421 | -15.6% | 0.01% | -11.1% |
Q2 2022 | $30,000 | 0.0% | 499 | +4.0% | 0.01% | 0.0% |
Q1 2022 | $30,000 | -16.7% | 480 | +2.1% | 0.01% | -25.0% |
Q4 2021 | $36,000 | -18.2% | 470 | +18.7% | 0.01% | -55.6% |
Q3 2021 | $44,000 | -33.3% | 396 | -3.4% | 0.03% | -40.0% |
Q2 2021 | $66,000 | +13.8% | 410 | -14.2% | 0.04% | +2.3% |
Q1 2021 | $58,000 | -30.1% | 478 | -12.3% | 0.04% | -31.2% |
Q4 2020 | $83,000 | +27.7% | 545 | -29.9% | 0.06% | +18.5% |
Q3 2020 | $65,000 | +20.4% | 778 | +6.6% | 0.05% | +20.0% |
Q2 2020 | $54,000 | +74.2% | 730 | 0.0% | 0.04% | +40.6% |
Q1 2020 | $31,000 | -18.4% | 730 | +17.6% | 0.03% | -59.0% |
Q4 2019 | $38,000 | +65.2% | 621 | +9.5% | 0.08% | +56.0% |
Q3 2019 | $23,000 | -11.5% | 567 | +3.8% | 0.05% | -20.6% |
Q2 2019 | $26,000 | +160.0% | 546 | +96.4% | 0.06% | +31.2% |
Q1 2019 | $10,000 | – | 278 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |